文献速递血栓与止血

癌症患者静脉血栓栓塞症临床风险评估评分的验证:一项基于人群的队列研究

Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study.
PubMed 文献 · J Thromb Haemost · 2024-10-29

在丹麦中部地区2012至2020年首次诊断癌症并启动系统治疗的12471例患者中验证新的癌症相关血栓形成(CAT)风险评分与Khorana评分。416例(3.3%)发生VTE,CAT评分C统计量为0.71(95%CI 0.68-0.74),Khorana评分为0.66(95%CI 0.63-0.70)。CAT评分高危组6175例6个月累积VTE发生率为5.0%,低危组6296例为1.7%。

要点

  • 新CAT评分C统计量0.71(95%CI 0.68-0.74),高于Khorana评分的0.66(95%CI 0.63-0.70)。
  • CAT评分高危组6175例6个月累积VTE发生率5.0%,低危组6296例为1.7%。
  • Khorana评分高危组4263例6个月累积VTE发生率5.2%,低危组8208例为2.4%。

核心结论

  • 新CAT评分的区分能力与推导研究报道的相似,C统计量在数值上高于Khorana评分,研究结果支持实施新CAT评分以识别VTE高风险的门诊癌症患者。

研究设计与样本

  • 基于人群的队列研究,使用丹麦中部地区医疗登记数据和电子病历,纳入2012至2020年首次诊断癌症并启动系统治疗的12471例患者,随访6个月。

主要发现

  • 12471例患者中416例(3.3%)发生VTE;新CAT评分C统计量0.71(95%CI 0.68-0.74),Khorana评分0.66(95%CI 0.63-0.70)。
  • 新CAT评分高危组6175例6个月累积VTE发生率为5.0%,低危组6296例为1.7%。
  • Khorana评分高危组4263例6个月累积VTE发生率为5.2%,低危组8208例为2.4%。

关键数值与推荐

  • 指南推荐使用风险评估工具识别VTE高风险的流动癌症患者。
  • 新CAT评分C统计量0.71(95%CI 0.68-0.74),Khorana评分C统计量0.66(95%CI 0.63-0.70)。

临床怎么用

  • 研究结果支持实施新CAT评分以识别VTE高风险的流动癌症患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend using risk assessment tools to identify ambulatory patients with cancer at high risk of venous thromboembolism (VTE). OBJECTIVES: We aimed to validate a new cancer-associated thrombosis (CAT) risk score in a population-based healthcare setting. METHODS: We used healthcare registry data and electronic medical records from the Central Denmark Region to calculate the new CAT risk score and the guideline-recommended Khorana score in patients with a first-time cancer diagnosis who initiated systemic cancer therapy. Patients were followed for 6 months after initiation of therapy. The outcome was any VTE identified through hospital discharge diagnoses. Discrimination was assessed using C statistics. RESULTS: We included 12 471 patients from 2012 to 2020. Of these, 416 (3.3%) developed VTE. The C statistic was 0.71 (95% CI, 0.68-0.74) for the new CAT score and 0.66 (95% CI, 0.63-0.70) for the Khorana score. The 6-month cumulative VTE incidence was 5.0% in 6175 patients classified as high risk by the new CAT score compared with 1.7% in 6296 patients classified as low risk. The 6-month cumulative VTE incidence was 5.2% in 4263 patients classified as high risk by the Khorana score compared with 2.4% in 8208 patients classified as low risk. CONCLUSION: The new CAT score had a discriminatory ability similar to that reported in the derivation study. The C statistic was numerically higher than that of the Khorana score. Our findings support the implementation of the new CAT score to identify ambulatory patients with cancer who are at high risk of VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lanting V, Vágó E, Horváth-Puhó E, et al. Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study. J Thromb Haemost. 2024. PMID: 39481543. doi:10.1016/j.jtha.2024.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。